Cardiomyocyte dedifferentiation may be an important source of proliferating cardiomyocytes facilitating cardiac repair. Cardiomyocyte dedifferentiation and proliferation induced by oncostatin-M (OSM) is characterized by sarcomere degeneration. However, the mechanism underlying sarcomere degeneration remains unclear. We hypothesized that this process may involve matrix metalloproteinase-2 (MMP-2), a key protease localized at the sarcomere in cardiomyocytes. We tested the hypothesis that MMP-2 is involved in the sarcomere degeneration that characterizes cardiomyocyte dedifferentiation. Confocal immunofluorescence and biochemical methods were used to explore the role of MMP-2 in OSM-induced dedifferentiation of neonatal rat ventricular myocytes (NRVM). OSM caused a concentration-and time-dependent loss of sarcomeric ␣-actinin and troponin-I in NRVM. Upon OSM-treatment, the mature sarcomere transformed to a phenotype resembling a lessdeveloped sarcomere, i.e., loss of sarcomeric proteins and Z-disk transformed into disconnected Z bodies, characteristic of immature myofibrils. OSM dose dependently increased MMP-2 activity. Both the pan-MMP inhibitor GM6001 and the selective MMP-2 inhibitor ARP 100 prevented sarcomere degeneration induced by OSM treatment. OSM also induced NRVM cell cycling and increased methylthiazolyl-tetrazolium (MTT) staining, preventable by MMP inhibition. These results suggest that MMP-2 mediates sarcomere degeneration in OSM-induced cardiomyocyte dedifferentiation and thus potentially contributes to cardiomyocyte regeneration. 
NEW & NOTEWORTHY

The cytokine oncostatin-M (OSM) can induce cardiomyocyte dedifferentiation, associated with sarcomere degeneration. We find that OSM treatment of cardiomyocytes increases matrix metalloproteinase-2 (MMP-2) expression and activity and that pharmaceutical inhibition of MMP-2 prevents OSM-induced sarcomere degeneration. This suggests a previously unknown role for MMP-2 in modulation of sarcomere structure and integrity.
HEART FAILURE REMAINS THE leading cause of mortality in the developed world. This is largely due to the limited capacity of adult human cardiomyocytes to divide and replace ventricular myocardium lost from infarcts or other injury. Although human heart cells are renewed throughout life at a low rate (6), the mechanism is unknown. One possibility is that adult cardiomyocytes can "dedifferentiate," losing characteristics of mature cardiomyocytes such as organized sarcomeric structures but regaining the ability to proliferate. Although not without controversy, supporting evidence has been found in mammals and lower vertebrates (8, 11, 17, 18) .
Because the sarcomere structure occupies a large volume of the mature cardiomyocyte, it physically impedes mitosis and cytokinesis (2) . Sarcomere degeneration and its final stage, full sarcomere disassembly, are likely prerequisite tasks for cardiomyocyte proliferation. Indeed, a dramatic decrease in sarcomeric proteins or structure has been observed in regenerating hearts in lower vertebrates and mice (11, 15, 16) .
Several sarcomeric proteins can be proteolyzed by matrix metalloproteinase-2 (MMP-2), which, in addition to its classical role as an extracellular protease, is partially retained within the cytosol due to an inefficient signal sequence (4). MMP-2 is associated with the sarcomere in both adult and neonatal cardiomyocytes and can cleave sarcomeric ␣-actinin, troponin I, myosin light chain-1, and titin in vitro and in vivo (reviewed in Ref. 5 ). We therefore hypothesized that MMP-2 contributes to sarcomere degeneration during cardiomyocyte dedifferentiation.
Cardiomyocyte dedifferentiation and sarcomere degeneration is promoted by the cytokine oncostatin-M (OSM), both in vitro and in vivo (15, 33) . OSM appears to trigger these effects via activation of its type II receptor, which stimulates a Ras/ Raf/MEK/Erk signaling cascade. This results in increased expression of progenitor or fetal gene markers, which were considered indicative of cardiomyocyte dedifferentiation. Interestingly, OSM has been shown to stimulate MMP expression in trophoblasts and chondrocytes (13, 29) in a Rafdependent fashion (14) .
Previous studies investigating the effects of OSM on cardiomyocyte dedifferentiation used adult mouse cardiomyocytes, with the rationale that mature cardiomyocytes may better replicate the in vivo situation. However, control adult cardiomyocytes had already lost their original striated sarcomeric appearance by the experimental endpoint (15, 20, 27) . Our model is based on neonatal rat ventricular myocytes (NRVM), which, unlike adult mouse cardiomyocytes, retain well-defined sarcomeric structure and spontaneous contractile activity in culture. While this model also has limitations compared with those used in other reports, with it we can evaluate a potential role of OSM in sarcomere degeneration as NRVM maintain functionally intact and contractile sarcomeric structures. Fur-thermore, rats exhibit an OSM signaling response much more similar to humans than is the case for mice (7) .
We therefore investigated whether MMP-2 could mediate OSM-induced sarcomere degeneration. MMP-2 activity and protein levels were increased by OSM treatment, and inhibition of MMP-2 abrogated the effect of OSM on sarcomeric structure and protein levels, as well as on cellular proliferation.
MATERIALS AND METHODS
NRVM isolation and culture. This study was conducted according to the Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care and was approved by the Animal Care and Use Committee of the University of Alberta. NRVM were isolated and cultured from 1-to 2-day-old Sprague-Dawley rats. Hearts were removed and ventricles were minced and digested with collagenase II (0.10% wt/vol), trypsin (0.05% wt/vol), and DNase (0.025% wt/vol) in phosphate-buffered saline at 37°C for 20 min. The digested tissue was centrifuged at 200 g for 1 min at 4°C in 20 ml of DMEM-F12 media (Sigma-Aldrich D6421) containing 20% fetal bovine serum (Invitrogen) and 50 g/ml gentamycin. The first supernatant was discarded and the pellet was added to the DNase/collagenase/trypsin buffer for further digestion at 37°C for 20 min. Two further digestion/centrifugation steps were performed. Collected supernatants were then pooled and centrifuged at 300 g for 7 min at 4°C. The resulting pellet was resuspended in 10 ml of culture medium (DMEM-F12 containing 10% fetal bovine serum and 50 g/ml gentamycin), filtered through a cell strainer (BD Biosciences), and preplated for 60 -90 min at 37°C to allow fibroblasts to attach. Nonadherent cells were removed and added to 35-mm dishes (Falcon) at a density of 1.8 -2.0 ϫ 10 6 cells/dish and incubated at 37°C in culture media.
Two days after isolation, cells were treated with OSM or vehicle along with MMP inhibitors or DMSO vehicle at the specified concentrations in culture medium. Media were changed and NRVM retreated every 2 days. NRVM were washed with PBS then lysed in RIPA buffer (Sigma-Aldrich R0278) with the addition of a proteinase inhibitor cocktail (Sigma P8340). Cell debris was pelleted (10 000 g, 5 min), and the supernatant was collected as the cell extract.
Methyl-thiazolyl-tetrazolium cell proliferation assay. NRVM were incubated 3.5 h at 37°C in 5 mg/ml methyl-thiazolyl-tetrazolium (MTT; Sigma M2128) dissolved in PBS. The MTT reaction product was dissolved in a 4 mM HCl, 0.1% NP-40 solution in isopropanol.
Absorbance was recorded at 590 nm. Antibodies and chemicals. The primary antibodies used were as follows: ␣-actinin (Abcam ab9465), titin (M8 epitope, provided by Dieter Fuerst, University of Bonn), GAPDH (Cell Signaling Technology 2118S), MMP-2 (Millipore MAB3308), troponin I (MA-1040; IPOC, Toronto, Canada), and Ki67 (Abcam ab15580). ARP 100 and GM 6001 were from Tocris Bioscience, and ONO-4817 was a gift from Ono Pharmaceutical. Recombinant mouse OSM was from R&D Systems. Mouse OSM shows a similar activation profile as rat OSM to rat cells (7) . OSM was dissolved 25 g/ml in PBS with 0.1% bovine serum albumin, aliquoted, and stored at Ϫ80°C.
Immunofluorescence imaging. Cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min. After being washed with PBS, cells were permeabilized for 1 min with 0.25% Triton X-100, and 0.2% BSA in PBS. Cells were then incubated with primary antibodies (1:1000 dilution). Then, secondary antibodies were conjugated to either AlexaFluor 488 or 568 (Invitrogen; 1:2,000 dilution) in PBS, 0.2% BSA for 1 h each and then washed three times with PBS. Cells were then mounted in ProLong Antifade with DAPI (Invitrogen). The images were acquired using a ϫ60 oil objective (Olympus 60X/1.42) on a multichannel spinning disc confocal microscope (1X81F-3; Olympus) and analyzed with Volocity 6.1.1 (PerkinElmer).
Western blots. Cell lysate protein content was determined by the Bradford method (Bio-Rad protein assay). Equal amounts of protein were loaded and electrophoresed on either 6 or 10% SDS-PAGE gels and electroblotted onto PVDF membranes (Bio-Rad). Membranes were blocked in 5% milk-TTBS (0.01 M Tris, pH 7.6, 0.1% Tween, and 0.1 M NaCl) for 2 h at room temperature and probed with primary antibody overnight at 4°C in blocking solution. Membranes were washed five times for 7 min in TTBS and incubated with horseradish peroxidiseconjugated anti-mouse or anti-rabbit secondary antibody (Cedarlane, Burlington, Ontario, Canada) in blocking solution for 1 h at room temperature. Bands were visualized with an ECL Prime chemiluminescence kit (Amersham Biosciences), and band intensities were analyzed by ImageJ 1.47 (National Institutes of Health, Bethesda, MD).
Gelatin zymography. Gelatin zymography was performed on cell lysates to assess MMP-2 activity. Cell lysates were mixed with nonreducing sample loading buffer and equal amounts were loaded onto 8% polyacrylamide gels copolymerized with 2 mg/ml gelatin. Conditioned media from the MMP-2 and MMP-9-secreting cell line HT-1080 were used as a standard for MMP-2 and MMP-9. Following electrophoresis, gels were rinsed in 2.5% Triton X-100 (3 ϫ 20 min) and then kept in incubation buffer overnight (18 h) at 37°C. Composition of incubation buffer was as follows (in mM): 50 Tris·HCl, 5 CaCl 2, 150 NaCl, and 0.05% NaN3. After incubation, gels were stained in 0.05% Coomassie brilliant blue for 2 h and destained. Zymogram band intensities were analyzed by ImageJ 1.47 (National Institutes of Health).
Statistical analysis. The relationship between OSM concentration, treatment duration and MMP-2 protein levels or activities were calculated as Pearson correlation coefficients. One-or two-way ANOVA followed by Fisher's least significant difference or Dunnet's post hoc test, as appropriate, were used to analyze differences between multiple groups. For simple comparison of two groups, an unpaired t-test was used. All calculations were performed using Prism 5 (GraphPad Software). Differences were considered significant at P Ͻ 0.05. OSM for 4 days and analyzed the appearance of sarcomeric proteins using confocal immunofluorescence microscopy. Importantly, and in contrast to the loss of sarcomere structure, even in control adult rat cardiomyocytes cultured for 4 days (15), control NRVM after 4 days continued to show spontaneous contractile activity and maintained excellent sarcomere structure (Fig. 1) . OSM (200 ng/ml) for 4 days induced marked sarcomere degeneration (Fig. 1) . The organized, striated staining pattern of the sarcomeric proteins ␣-actinin, titin (M-line region), and troponin I of untreated NRVM was not evident in OSM-treated cells. OSM caused a concentration-dependent decrease in the intensity of ␣-actinin, titin, and troponin I immunofluorescence. Accordingly, Z discs were transformed to Z bodies (arrows in Fig. 1A) , characteristic of immature myofibrils (24, 28) .
RESULTS
OSM induces dose-and time-dependent sarcomere degeneration in NRVM.
There was a time-dependent effect on sarcomere degeneration (Fig. 1B) by 200 ng/ml OSM. Following a lag period of 3 days, OSM transformed the sarcomere structure of NRVM to a more immature pattern. The organized striation pattern of Z-bands stained by ␣-actinin devolved to disconnected Z bodies (arrows in Fig. 1B ). Titin and troponin I immunostaining almost disappeared after 4 days of OSM-induced dedifferentiation.
OSM increases MMP-2 expression and activity. Given that MMP-2 is upregulated in proliferative disorders such as cancer (12) , and the close relationship between MMP-2 and the sarcomere (5), we hypothesized that OSM could upregulate MMP-2. We found that OSM concentration dependently increased MMP-2 protein level in cell lysates, with maximal levels at 100 -200 ng/ml of OSM for 4 days (Fig. 2A) . OSM (200 ng/ml) maximally increased MMP-2 protein levels ( Fig.  2B ) and activity (Fig. 2C ) after 4 days. There was no MMP-9 activity in any of the assayed samples.
Inhibition of MMP-2 prevents OSM-induced sarcomere degeneration.
To determine if MMP-2 is playing a causative role in OSM-induced sarcomere degeneration, we assessed the effects of MMP inhibitors on sarcomere degeneration. Immunofluorescence analysis showed that either a pan-MMP inhibitor (GM6001; 5 M) (10), an MMP-2 selective inhibitor (ARP 100; 10 M) (22) , or an MMP-1-sparing inhibitor (ONO-4817; 10 M) (31) all rescued the OSM-induced loss of sarcomeric ␣-actinin and titin immunostaining (Fig. 3A) . This was also seen on Western blots of the cell homogenates for ␣-actinin content (Fig. 3B) , whereby OSM caused a loss in ␣-actinin, a known MMP-2 target (26), which was prevented by MMP inhibitors. The decreased protein level in Western blots suggests that the decreased ␣-actinin immunoreactivity observed in Figs. 1 and 3A is due to protein loss, rather than simply disassembly of ␣-actinin from the sarcomeric apparatus.
Inhibition of MMP-2 prevents OSM-induced cellular proliferation. Treatment of adult cardiomyocytes with OSM resulted in an increase in markers of enhanced cell-cycle progression (15) . We used immunofluorescence to determine the proportion of NRVM with Ki-67 positive nuclei. Three-day treatment with OSM (200 ng/ml) significantly increased the proportion of NRVM with Ki-67-positive nuclei (Fig. 4A) , indicative of increased cell cycling.
Because of the low-throughput nature of the Ki-67 labeling assay, and questions about the specificity for Ki67 with regard to cardiomyocyte proliferation (17), we used the MTT cell proliferation assay (19) to investigate if MMP inhibitors alter the OSM-induced increase in NRVM proliferation. Four-day OSM concentration dependently increased cell proliferation to a maximum at 200 ng/ml (Fig. 4B) . This increase was diminished by GM6001 or ARP 100.
DISCUSSION
We showed here that one or more MMPs, possibly MMP-2, play a key role in OSM-induced sarcomere degeneration. MMP-2 is colocalized with and is responsible for the proteolysis of the sarcomeric proteins troponin I (30), ␣-actinin (26), and titin (3) in acute myocardial oxidative stress injury such as ischemia and reperfusion. OSM induced a time-and concentration-dependent reduction in their levels, which was blocked by MMP inhibitors including one selective for MMP-2. Although sarcomeric proteins are downregulated in OSM-induced dedifferentiation (20) , a role of the sarcomeric protease MMP-2 implicates a proteolytic process in sarcomere degeneration. We also extended the evidence for OSM-induced sarcomere degeneration and cardiomyocyte dedifferentiation from postmitotic adult mouse cardiomyocytes (15) to rat neonatal cardiomyocytes capable of a limited degree of mitotic activity (9) . Whether or not sarcomere degeneration is a sign of cardiomyocyte dedifferentiation (32) , NRVM may be a useful tool to investigate this issue. However, it is of critical importance to test whether MMP-2 inhibition prevents these effects of OSM in both adult cardiomyocytes and in the myocardium, as well as using genetic techniques to decisively implicate MMP-2 as opposed to other possible MMPs. Further studies should also assess the physiological and metabolic impact of modulation of MMP activities in cardiomyocytes exposed to OSM. It is also important to validate the impact of MMP inhibition in OSM-treated cardiomyocytes with more specific techniques, such as flow cytometry using carboxyfluorescein diacetate succinimidyl ester staining or bromodeoxyuridine incorporation.
We previously showed that MMPs are not required for sarcomere disassembly during neonatal cardiomyocyte mitosis (9) . The mechanism driving sarcomere disassembly in mitotic cardiomyocytes is thus likely distinct from that in OSMinduced sarcomere degeneration. Indeed, OSM-dedifferenti- Fig. 4 . Inhibition of MMP-2 prevents OSM-induced NRVM proliferation. A: 200 ng/ml OSM (3 days) results in enhanced cellular proliferation, as indicated by an increased proportion of NRVM positive for Ki-67 (n ϭ 3; *P ϭ 0.026). Representative immunofluorescence images for Ki67 labeling are also shown, in the absence (Ϫ) or presence (ϩ) of OSM (DAPI: blue; Ki67: green). B: methyl-thiazolyl-tetrazolium (MTT) cellular proliferation assay showed an increase in NRVM proliferation with increased OSM concentration, after 4 d of OSM exposure. This dose-dependent increase in proliferation was largely prevented by MMP inhibitors (n ϭ 2; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, two-way ANOVA with Dunnet's multiple comparisons test). ated cardiomyocytes do not spontaneously regain sarcomeric structure or contractile function, unlike cardiomyocytes proceeding through mitosis (21) .
OSM was cardioprotective in mice subjected to myocardial infarct (15, 25, 34) . However, OSM had a detrimental effect on cardiac function in chronic dilated cardiomyopathy, with genetic or immunological abrogation of OSM signaling exerting a protective effect (15, 21) . Consequently, there is a need to better understand the mechanisms of cardiac dedifferentiation and the role played by OSM, with the eventual goal being to take advantage of this process in a clinical setting (1) .
In conclusion, we have shown that OSM-induced sarcomere degeneration and cardiomyocyte proliferation occur in rat neonatal cardiomyocytes and, critically, that a MMP, likely MMP-2, is a key modulator of this process. This provides another tool to investigate cardiomyocyte dedifferentiation, the nature, and utility, of which still remains a subject of debate (1, 18, 23, 27, 32) . More fundamentally, understanding this process may be key to developing regeneration-based therapies for heart injury.
